NCT05395338View on ClinicalTrials.gov

1-year Clinical Outcomes in Recombinant Tissue Plasminogen Activator (Rt-PA) Treated Chinese Acute Ischaemic Stroke (AIS) Patients

CompletedOBSERVATIONAL
Enrollment

12,551

Participants

Timeline

Start Date

April 12, 2022

Primary Completion Date

November 30, 2022

Study Completion Date

November 30, 2022

Conditions
Stroke
Interventions
DRUG

rt-PA

Recombinant Tissue Plasminogen Activator

Trial Locations (1)

200040

Boehringer Ingelheim (China) Investment Co., ltd., Shanghai

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT05395338 - 1-year Clinical Outcomes in Recombinant Tissue Plasminogen Activator (Rt-PA) Treated Chinese Acute Ischaemic Stroke (AIS) Patients | Biotech Hunter | Biotech Hunter